Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-363, KITE-753, KITE-197, and anitocabtagene autoleucel in participants of Kite-sponsored interventional studies.
Solid and Hematological Malignancies
BIOLOGICAL: Axicabtagene Ciloleucel|BIOLOGICAL: Brexucabtagene Autoleucel|BIOLOGICAL: Anitocabtagene autleucel|BIOLOGICAL: KITE-753|BIOLOGICAL: KITE-197|BIOLOGICAL: KITE-363
Percentage of Participants Experiencing Late-onset Targeted Adverse Events (AEs), Targeted AEs include late-onset targeted AEs suspected to be possibly related to gene-modified cells include neurologic disorders, autoimmune disorders, hematologic disorders, serious infections, and new malignancies., Up to 15 years|Percentage of Participants Experiencing Late-onset Targeted Serious Adverse Events (SAEs), Targeted SAEs include late-onset targeted SAEs suspected to be possibly related to gene-modified cells include neurologic disorders, autoimmune disorders, hematologic disorders, serious infections, and new malignancies., Up to 15 years|Height of Pediatric and Adolescent Participants, Up to 15 years|Weight of Pediatric and Adolescent Participants, Up to 15 years|Sexual Maturation of Pediatric and Adolescent Participants Assessed by Tanner Pubertal Stage Scale Score, The Tanner Pubertal Stage Scale is a measure of pubertal development (sexual maturation) in children and adolescents with components described for each sex, rated separately on a scale of stage one to stage five, with 1 for preadolescent and 5 for mature/adult., Up to 15 years
Time to Subsequent Anticancer Therapies, Time to subsequent anticancer therapies will be assessed only per regulatory request or sponsor needs., Up to 15 years|Survival Status Assessment, Survival status will be assessed as the length of time from the participant's first dose date of study drug to death during the study due to any cause or last date of being alive during the study. Survival status will be assessed only per regulatory request or sponsor needs., Up to 15 years|Percentage of Participants With Cause of Death, Up to 15 years|Overall Rate of Replication-competent Retrovirus/Replication-competent Lentivirus (RCR/RCL), Up to 15 years|Percentage of Participants With Vector Integration Site(s) for Replication-competent Retrovirus/Replication-competent Lentivirus (RCR/RCL) or Insertional Mutagenesis for Confirmed Events Related to the Cell Therapy Product, Up to 15 years|Percentage of Participants With Status of Primary Malignant Disease, Up to 15 years
The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-363, KITE-753, KITE-197, and anitocabtagene autoleucel in participants of Kite-sponsored interventional studies.